GASTROGRAFIN 10 %
DIATRIZOATE SODIUM : 10 % DIATRIZOATE MEGLUMINE : 66 % · DIN 02228564 · BRACCO IMAGING CANADA
Health Canada status: MARKETED
What is GASTROGRAFIN?
GASTROGRAFIN 10 % contains DIATRIZOATE SODIUM : 10 % DIATRIZOATE MEGLUMINE : 66 %. It is listed in the Health Canada Drug Product Database under DIN 02228564, held by BRACCO IMAGING CANADA, supplied as SOLUTION for ORAL ; RECTAL administration. Health Canada currently lists it as marketed, status dated 22-Apr-1997. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02228564 |
|---|---|
| Brand name | GASTROGRAFIN |
| Generic / active ingredient | DIATRIZOATE SODIUM : 10 % DIATRIZOATE MEGLUMINE : 66 % |
| Manufacturer | BRACCO IMAGING CANADA |
| Strength | 10 % |
| Dosage form | SOLUTION |
| Route of administration | ORAL ; RECTAL |
| Schedule | Ethical |
| ATC code | V08AA01 DIATRIZOIC ACID |
| AHFS class | 36:68.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 22-Apr-1997 |
| Original market date | 1998-07-20 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code V08AA01 DIATRIZOIC ACID. 1 of 30 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| GASTROGRAFIN LIQ | 10 % | LIQUID | SQUIBB DIAGNOSTICS, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | CANCELLED POST MARKET | DIN 01995669 |
| HYPAQUE ORAL LIQUID - 50G/120ML | 50 G / 120 ML | LIQUID | NYCOMED IMAGING A.S. | CANCELLED POST MARKET | DIN 02180626 |
| HYPAQUE ORAL LIQUID 50GM/120ML | 50 G / 120 ML | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02026902 |
| HYPAQUE ORAL POWDER | 997.4 MG | POWDER | GE HEALTHCARE CANADA INC | CANCELLED POST MARKET | DIN 02180685 |
| HYPAQUE ORAL POWDER 0.9974G/G | 997.4 MG | POWDER | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02026988 |
| HYPAQUE PWR 100% | 100 % | POWDER | STERLING WINTHROP INC. | CANCELLED POST MARKET | DIN 01905007 |
| HYPAQUE SODIUM 50% - LIQ IV | 50 % | LIQUID | NYCOMED IMAGING A.S. | CANCELLED POST MARKET | DIN 02180650 |
| HYPAQUE SODIUM 50% LIQ | 50 % | LIQUID | STERLING WINTHROP INC. | CANCELLED POST MARKET | DIN 01902768 |
| HYPAQUE SODIUM LIQ 50% | 50 % | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02017784 |
| HYPAQUE-M 18% | 18 % | SOLUTION | AMERSHAM HEALTH INC | CANCELLED POST MARKET | DIN 02180634 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.